

Claims 1-7 (canceled).

8. (currently amended) An isolated FGF homolog polypeptide selected from the group consisting of:

- a) polypeptide molecules comprising an amino acid sequence as shown in SEQ ID NO: 2 from residue 28 (Glu) to residue 175 (Met);
- b) allelic variants of (a); and
- c) polypeptide molecules that are at least ~~60%~~ 80% identical to SEQ ID NO: 2 from amino acid residue 28 (Glu) to amino acid residue 175 (Met).

9. (currently amended) An isolated FGF homolog polypeptide selected from the group consisting of:

- a) polypeptide molecules comprising an amino acid sequence as shown in SEQ ID NO: 2 from residue 28 (Glu) to residue 196 (Lys);
- b) allelic variants of (a); and
- c) polypeptide molecules that are at least ~~60%~~ 80% identical to SEQ ID NO: 2 from amino acid residue 28 (Glu) to amino acid residue 196 (Lys).

10. (currently amended) An isolated FGF homolog polypeptide selected from the group consisting of:

- a) polypeptide molecules comprising an amino acid sequence as shown in SEQ ID NO: 2 from residue 28 (Glu) to residue 207 (Ala);
- b) allelic variants of (a); and
- c) polypeptide molecules that are at least ~~60%~~ 80% identical to the amino acids of SEQ ID NO: 2 from amino acid residue 28 (Glu) to amino acid residue 207 (Ala).

11. (original) The FGF homolog polypeptide of claim 8 further comprising a signal sequence.

12. (original) The FGF homolog polypeptide of claim 8 further comprising a signal sequence as shown in SEQ ID NO: 2 from amino acid residue 1 (Met) to amino acid residue 27 (Ala).

13. (original) A pharmaceutical composition comprising a purified FGF homolog polypeptide according to claim 8, in combination with a pharmaceutically acceptable vehicle.

Claims 14-20 (canceled).

21. (new) An isolated FGF homolog polypeptide of claim 8 wherein said polypeptide is at least 90% identical to SEQ ID NO: 2 from amino acid residue 28 (Glu) to amino acid residue 175 (Met).

22. (new) An isolated FGF homolog polypeptide of claim 8 wherein said polypeptide is at least 95% identical to SEQ ID NO: 2 from amino acid residue 28 (Glu) to amino acid residue 175 (Met).

23. (new) An isolated FGF homolog polypeptide of claim 8 wherein said polypeptide is at least 90% identical to SEQ ID NO: 2 from amino acid residue 28 (Glu) to amino acid residue 196 (Lys).

24. (new) An isolated FGF homolog polypeptide of claim 8 wherein said polypeptide is at least 95% identical to SEQ ID NO: 2 from amino acid residue 28 (Glu) to amino acid residue 196 (Lys).

25. (new) An isolated FGF homolog polypeptide of claim 8 wherein said polypeptide is at least 90% identical to SEQ ID NO: 2 from amino acid residue 28 (Glu) to amino acid residue 207 (Ala).

26. (new) An isolated FGF homolog polypeptide of claim 8 wherein said polypeptide is at least 95% identical to SEQ ID NO: 2 from amino acid residue 28 (Glu) to amino acid residue 207 (Ala).

27. (new) The FGF homolog polypeptide of claim 9 further comprising a signal sequence.

28. (new) The FGF homolog polypeptide of claim 9 further comprising a signal sequence as shown in SEQ ID NO: 2 from amino acid residue 1 (Met) to amino acid residue 27 (Ala).

29. (new) A pharmaceutical composition comprising a purified FGF homolog polypeptide according to claim 9, in combination with a pharmaceutically acceptable vehicle.

30. (new) The FGF homolog polypeptide of claim 10 further comprising a signal sequence.

31. (new) The FGF homolog polypeptide of claim 10 further comprising a signal sequence as shown in SEQ ID NO: 2 from amino acid residue 1 (Met) to amino acid residue 27 (Ala).

32. (new) A pharmaceutical composition comprising a purified FGF homolog polypeptide according to claim 10, in combination with a pharmaceutically acceptable vehicle.

33. (new) An isolated FGF homolog polypeptide selected from the group consisting of:

- a) polypeptide molecules comprising an amino acid sequence as shown in SEQ ID NO: 2 from residue 58 (Tyr) to residue 175 (Met);
- b) allelic variants of (a); and
- c) polypeptide molecules that are at least 80% identical to SEQ ID NO: 2 from amino acid residue 58 (Tyr) to amino acid residue 175 (Met).

34. (new) An isolated FGF homolog polypeptide selected from the group consisting of:

- a) polypeptide molecules comprising an amino acid sequence as shown in SEQ ID NO: 2 from residue 58 (Tyr) to residue 196 (Lys);
- b) allelic variants of (a); and
- c) polypeptide molecules that are at least 80% identical to SEQ ID NO: 2 from amino acid residue 58 (Tyr) to amino acid residue 196 (Lys).

35. (new) An isolated FGF homolog polypeptide selected from the group consisting of:

- a) polypeptide molecules comprising an amino acid sequence as shown in SEQ ID NO: 2 from residue 58 (Tyr) to residue 207 (Ala);

- b) allelic variants of (a); and
- c) polypeptide molecules that are at least 80% identical to the amino acids of SEQ ID NO: 2 from amino acid residue 58 (Tyr) to amino acid residue 207 (Ala).